ACTIVE

BioLyo Technologies

Export PDF
Financial year 2024 · closed on 31/12/2024
Net result
-189,4 k €
-1684.0% YoY
Gross margin
1 M €
+19.1% YoY
Equity
102,6 k €
-64.9% YoY
Workforce
12,4 ETP
+19.2% YoY

What does BioLyo Technologies do?

BioLyo Technologies is a Private limited company incorporated in 2020. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gent. It employs on average 12,4 ETP workers (FTE).

Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0741.579.648
Incorporation
15/01/2020
Legal form
Private limited company
Registered office
Technologiepark-Zwijnaarde 94
9052 Gent · FlandreSee on map
Contributed capital
592 745,50 €
Latest accounts
31/12/2024
Average workforce
12,4 ETP
Activities (NACE)
72101Research and experimental development on natural sciences and engineering· main72110Research and experimental development on biotechnology21100Manufacture of basic pharmaceutical products21100Manufacture of basic pharmaceutical products
Contacts
1 public detail availableLog in to view
Signals
Positive EBITDAHealthy social debts
View the BCE/KBO Public Search record →
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 5 financial years

20242023202220212020
Income statement
Gross margin1 M €872,1 k €582 k €434,3 k €-58,7 k €
EBITDA14,4 k €171,6 k €101,4 k €118,3 k €-232,3 k €
Operating result-163,9 k €14,6 k €2,6 k €54,5 k €-314,3 k €
Net result-189,4 k €-10,6 k €-8,2 k €47,3 k €-329,2 k €
Balance sheet
Equity102,6 k €292 k €302,6 k €160,9 k €13,6 k €
Total assets1,6 M €1,7 M €1,2 M €763,8 k €474,3 k €
Cash150,1 k €607,6 k €441,1 k €139,6 k €49,3 k €
Debts1,5 M €1,4 M €871,8 k €600,2 k €458,5 k €
Other
Workforce12,4 ETP10,4 ETP6,9 ETP4,7 ETP4,0 ETP
Estimate

Indicative valuation

As an indication, this company is worth

between 0 € and 100 k€
See the valuation
Governance

Board of directors

Seen on filing of 31/12/2024 · 3 active · 2 ended

Active mandates

Keith Rubin

Director

Active
Kenneth Solovay

Director · until 14 décembre 2024

Active
THALEN BIOTECH CONSULTANCY

Director · 0607.985.607

Represented by Marcel Thalen

Active

Ended mandates

Kenneth Solovay

Director

Ended
THALEN BIOTECH CONSULTANCY

Director · 0607.985.607

Represented by Marcel Thalen

Ended
At this address

Other companies at this address

CompanyCBE no.
AnimAb● Active
0747.674.614
ExeVir Bio● Active
0750.495.334
Flindr Labs● Active
1014.117.578
Protealis● Active
0765.251.410
YAKULT HONSHA EUROPEAN RESEARCH CENTER FOR MICROBIOLOGY● Active
0873.953.667
Zomagen Biosciences Belgium● Active
0744.519.837
Annual accounts

Full financial information

20242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202401/01/202301/01/202201/01/202113/01/2020
Closing of the financial year31/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months
Filing date29/09/202504/09/202420/06/202305/07/202214/09/2021
General meeting22/09/202523/08/202409/06/202310/06/202224/08/2021
Currency of the financial yearEUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

5 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202422/09/202529/09/2025DutchPDF
Abridged model31/12/202323/08/202404/09/2024DutchPDF
Abridged model31/12/202209/06/202320/06/2023DutchPDF
Abridged model31/12/202110/06/202205/07/2022DutchPDF
Abridged model31/12/202024/08/202114/09/2021DutchPDF
Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 0 € and 100 k€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2024 · 3 active · 2 ended

Active mandates

Keith Rubin

Director

Active
Kenneth Solovay

Director · until 14 décembre 2024

Active
THALEN BIOTECH CONSULTANCY

Director · 0607.985.607

Represented by Marcel Thalen

Active

Ended mandates

Kenneth Solovay

Director

Ended
THALEN BIOTECH CONSULTANCY

Director · 0607.985.607

Represented by Marcel Thalen

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Mandates30/06/2025
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Other27/01/2025
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …)
    PDF
  • Registered office13/09/2022
    MAATSCHAPPELIJKE ZETEL
    PDF
  • Mandates07/07/2020
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Registered office24/04/2020
    MAATSCHAPPELIJKE ZETEL
    PDF
  • Other17/01/2020
    RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2024
    Annual accounts 2024-189,4 k €↓
  2. 2023
    Annual accounts 2023-10,6 k €↓
  3. 2022
    Annual accounts 2022-8,2 k €↓
  4. 2021
    Annual accounts 202147,3 k €↑
  5. 2020
    Annual accounts 2020-329,2 k €
  6. 15/01/2020
    IncorporationPrivate limited company